EGFR and non-small cell lung carcinoma: The ongoing ACHIEVE study showed a CNS ORR of 86.3% (19/22) in treatment‐naive EGFR‐mutant NSCLC patients with asymptomatic brain metastases treated with aumolertinib 165 mg [28].